Pharmaceutical and Clinical Evaluation of Hrudayarnavaras to its effect on Hyperlipidemia
Trial Snapshot
- Phase
- Unknown
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Reduced levels of Lipid Profiles Arrest of the progress of condition into atherosclerosis
Study Overview
Brief Summary
The proposed study was undertaken to investigate and establish the anti hyperlipidemic effect of a herbo mineral compound hrudayarnava ras the trial drug Hrudayarnava Rasa will be prepared in PG Deptof RS BK in Dr NRS Govt Ayurvedic College dosage125 mg twice in a day AnupanamKakamachi and Triphala kashayam of 30 ml along tablet for a period of 90 days with investigations of serum cholesterol and lipid profile every 30 days period Data obtained from the present study is reproducible to avoid the batch to batch variation this Hrudayarnavaras sample preparing in a large quantity the values of physicochemical parameters can be taken for quality assurance
Study Design
- Study Type
- Interventional
- Allocation
- Not Applicable
- Masking
- Open Label
Eligibility Criteria
- Ages
- 35.00 Year(s) to 75.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Hyperlipidemia Angio graphically documented Coronary artery disease Radiological confirmation through Angiogram Doppler studies etc Abnormalities present in ECG Echocardiography Stress test etc.
Exclusion Criteria
- •Age below 35 years Recent MI less than three months Patients with conduction problem Patient with uncontrolled hypertension Unstable Angina Serious concomitant disease of liver and or kidney.Any malignancy Undergoing treatment for any other serious illness Pregnant women.
Outcomes
Primary Outcomes
Reduced levels of Lipid Profiles Arrest of the progress of condition into atherosclerosis
Time Frame: Reduced levels of Lipid Profiles | Arrest of the progress of condition into atherosclerosis | c)Prevention of complications like CAD, MI and CVA etc.
c)Prevention of complications like CAD, MI and CVA etc.
Time Frame: Reduced levels of Lipid Profiles | Arrest of the progress of condition into atherosclerosis | c)Prevention of complications like CAD, MI and CVA etc.
Secondary Outcomes
- improvement generalcondition of the patient and can to their work easily(treatment period 90 days followup treatment for every 30 days)
- To reduce the serum lipid levels(6 months)